Combinations and modes of administration of therapeutic agents and combination therapy
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents (such as an anti-VEGF antibody), or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
1. A method of inhibiting tumor metastasis in an individual, comprising administering to the individual: a) an effective amount of a composition comprising nanoparticles comprising taxane coated with albumin, wherein the average diameter of the nanoparticles in the composition is no greater than about 200 nm, and wherein the effective amount of the taxane in the composition is about 60 mg/m 2 to about 300 mg/m 2 ; and b) an effective amount of an anti-VEGF antibody in the range of about 2 mg/kg to about 10 mg/kg.
2. The method of claim 1 , wherein the tumor metastasis is metastasis to lymph node.
3. The method of claim 1 , wherein the tumor metastasis is metastasis to the lung.
4. The method of claim 1 , wherein the tumor metastasis is metastasis of breast cancer.
5. The method of claim 1 , wherein at least about 40% of metastasis is inhibited.
6. The method of claim 1 , wherein at least about 80% of metastasis is inhibited.
7. The method of claim 1 , wherein the taxane is paclitaxel.
8. The method of claim 1 , wherein the albumin is human serum albumin.
9. The method of claim 1 , wherein the composition comprising nanoparticles comprising taxane coated with albumin and the anti-VEGF antibody are administered simultaneously.
10. The method of claim 1 , wherein the composition comprising nanoparticles comprising taxane coated with albumin and the anti-VEGF antibody are administered sequentially.
11. The method of claim 4 , wherein the taxane is paclitaxel.
12. The method of claim 4 , wherein the albumin is human serum albumin.
13. The method of claim 4 , wherein the composition comprising nanoparticles comprising taxane coated with albumin and the anti-VEGF antibody are administered simultaneously.
14. The method of claim 4 , wherein the composition comprising nanoparticles comprising taxane coated with albumin and the anti-VEGF antibody are administered sequentially.
15. The method of claim 6 , wherein the taxane is paclitaxel.
16. The method of claim 6 , wherein the albumin is human serum albumin.
17. The method of claim 6 , wherein the composition comprising nanoparticles comprising taxane coated with albumin and the anti-VEGF antibody are administered simultaneously.
18. The method of claim 6 , wherein the composition comprising nanoparticles comprising taxane coated with albumin and the anti-VEGF antibody are administered sequentially.
19. The method of claim 7 , wherein the composition comprising nanoparticles comprising paclitaxel coated with albumin and the anti-VEGF antibody are administered simultaneously.
20. The method of claim 7 , wherein the composition comprising nanoparticles comprising paclitaxel coated with albumin and the anti-VEGF antibody are administered sequentially.
21. The method of claim 11 , wherein the composition comprising nanoparticles comprising paclitaxel coated with albumin and the anti-VEGF antibody are administered simultaneously.
22. The method of claim 11 , wherein the composition comprising nanoparticles comprising paclitaxel coated with albumin and the anti-VEGF antibody are administered sequentially.
23. The method of claim 15 , wherein the composition comprising nanoparticles comprising paclitaxel coated with albumin and the anti-VEGF antibody are administered simultaneously.
24. The method of claim 15 , wherein the composition comprising nanoparticles comprising paclitaxel coated with albumin and the anti-VEGF antibody are administered sequentially.